Survival outcomes for patients with HR+/HER2- mBC remain suboptimal, despite first-line treatment strategies with endocrine therapy (ET). Greater understanding of the biology of HR+/HER2- mBC, including the role of biomarkers like ESR1 mutations, and the development of biopsy techniques for early mutation detection, have paved the way for personalized treatment approaches. In this 45-minute activity, medical oncologists Sara Hurvitz, MD, and Hope Rugo, MD, discuss key concepts in integrating these evidence-based advancements into clinical practice. They share their thoughts about selecting personalized treatment based on biomarkers, utilizing liquid biopsy techniques to guide therapy for ET resistance, and applying the latest evidence to overcome ET resistance and optimize patient outcomes.
This content is also availble as a podcast: You may listen here.
Course Credit:
1.00 AMA PRA Category 1 CreditTM
Dates:
Opens: 2025-04-10
Closes: 2026-04-10
Target Audience:
This activity is intended for community-and institution-based medical oncologists, pathologists, and other oncology healthcare providers such as nurse practitioners, physician associates, nurses, and pharmacists.
This activity is supported by an independent educational grant from Lilly.
Accreditation
The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Additional Content Planners
Alexa Basilio, PharmD, BCOP (Medical Writer)Employee: McKesson
Kam A. Newman, MD (Peer Reviewer)
No significant relationships to disclose.
Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.
All of the financial relationships listed for these individuals have been mitigated.
-
Sara A. Hurvitz, MD
Professor of Medicine
Smith Family Endowed Chair in Women’s Health
Head, Division of Hematology and Oncology | Senior Vice President, Clinical Research Division
Department of Medicine, UW Medicine | Fred Hutchinson Cancer Center
Seattle, Washington -
Hope S. Rugo, MD
Professor of Medicine
Winterhof Family Distinguished Professor of Breast Oncology
University of California San Francisco Comprehensive Cancer Center
San Francisco, California
Presenting Faculty
Downloads
Learning Objectives
- Improve knowledge of how biomarkers guide treatment decisions for patients with HR+/HER2- mBC, focusing on early detection and treatment planning
- Develop practical skills to effectively utilize liquid biopsy techniques to guide therapy for ET resistance in routine clinical practice
- Select appropriate ET treatment regimens for patients with HR+/HER2- mBC based on current guidelines, focusing on strategies to overcome ET resistance and optimize ET outcomes
Faculty Disclosures
Sara A. Hurvitz, MD
Advisory Board: BriaCell, Gilead
Consultant: BeiGene, BridgeBio, Luminate
Data Safety Monitoring Board: Atossa, InClin, Inc.
Research Support: Arvinas, AstraZeneca, Dantari, Daiichi Sankyo, Lilly, G1-Therapeutics, Genentech, Gilead, Greenwich LifeScience, Immunomedics, Jazz, Menarini, Novartis, Orum, Roche, Orinove, Pfizer, PUMA, Radius, Sanofi, Seattle Genetics, Seagen, Stemline Therapeutics, Zymeworks
Steering Committee: Boehringer Ingelheim, BriaCell, Orum
Hope S. Rugo, MD
Consultant: Chugai, Mylan, Napo, Puma, Sanofi
Research Support: Ambryx, AstraZeneca, Daiichi Sankyo, Genentech, Gilead Sciences, Lilly, Merck, Novartis, OBI Pharma, Pfizer, Roche, Stemline Therapeutics